BRAF and melanoma: The prospect of coupling the KMPAG signature with genomic profiling of other prevalent melanoma driver mutations (e.g., BRAF, NRAS) adds another layer of precision medicine, as it may reveal composite molecular phenotypes that inform unique susceptibility or resilience to various therapeutic interventions (26).